Hantz Financial Services, Inc. Biomarin Pharmaceutical Inc Transaction History
Hantz Financial Services, Inc.
- $5.74 Billion
- Q4 2024
A detailed history of Hantz Financial Services, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 121 shares of BMRN stock, worth $7,441. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121
Previous 121
-0.0%
Holding current value
$7,441
Previous $9,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BMRN
# of Institutions
632Shares Held
184MCall Options Held
2MPut Options Held
1.67M-
Black Rock Inc. New York, NY22.7MShares$1.4 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.19 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.12 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$907 Million0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$799 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11.4B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...